Monitoring late-onset toxicities in phase I trials using predicted risks

DOI10.1093/biostatistics/kxm044zbMath1143.62072OpenAlexW2167561655WikidataQ35804231 ScholiaQ35804231MaRDI QIDQ3526173

B. Nebiyou Bekele, Yu Shen, Peter F. Thall, Yuan Ji

Publication date: 25 September 2008

Published in: Biostatistics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1093/biostatistics/kxm044

zbMATH Keywords

Markov chain Monte Carlolatent variablesBayesian inferenceisotonic regressionadaptive designdose findingpredictive probabilityordinal modeling

Mathematics Subject Classification ID

Related Items (8)

Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment ⋮ Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial ⋮ Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates ⋮ Bayesian models and decision algorithms for complex early phase clinical trials ⋮ The adaptive accelerated biased coin design for phase I clinical trials ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ Risk-Group-Specific Dose Finding Based on an Average Toxicity Score ⋮ Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes

This page was built for publication: Monitoring late-onset toxicities in phase I trials using predicted risks